Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2017
Summary
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) pipeline Target constitutes close to 27 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Histone deacetylase 1 is an enzyme encoded by the HDAC1 gene. The protein encoded by this gene belongs to the histone deacetylase family and is a component of the histone deacetylase complex. It also interacts with retinoblastoma tumor-suppressor protein and this complex is a key element in the control of cell proliferation and differentiation. Together with metastasis-associated protein-2 MTA2, it deacetylates p53 and modulates its effect on cell growth and apoptosis. It plays an important role in transcriptional regulation, cell cycle progression and developmental events. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 1, 12 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Hematological Disorders, Genetic Disorders, Dermatology, Gastrointestinal, Immunology, Infectious Disease and Musculoskeletal Disorders which include indications Breast Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Follicular Lymphoma, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lung Cancer, Melanoma, Neuroblastoma, Solid Tumor, Thalassemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Essential Thrombocythemia, Liver Cancer, Mantle Cell Lymphoma, Metastatic Renal Cell Carcinoma, Neurodegenerative Diseases, Non-Hodgkin Lymphoma, Pancreatic Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Sickle Cell Disease, Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Type C, Adenoid Cystic Carcinoma (ACC), Alopecia, Alzheimer's Disease, Anaplastic Thyroid Cancer, Becker Muscular Dystrophy, Bone Disorders, Burkitt Lymphoma, Cervical Cancer, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), CNS Lymphoma, Depression, Duchenne Muscular Dystrophy, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gallbladder Cancer, Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leiomyosarcoma, Leukemias, Liver Fibrosis, Lung Adenocarcinoma, Lymphoma, Marginal Zone B-cell Lymphoma, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Metastatic Uveal Melanoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, Neurology, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Ductal Adenocarcinoma, Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Polycythemia Vera, Psychiatric Disorders, Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Renal Cell Carcinoma, Skin Cancer, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, T-Cell Leukemia and Thyroid Cancer.
Furthermore, this report also reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
- The report reviews Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics and enlists all their major and minor projects
- The report assesses Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Overview 8
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Development 9
Products under Development by Stage of Development 9
Products under Development by Therapy Area 10
Products under Development by Indication 11
Products under Development by Companies 17
Products under Development by Universities/Institutes 25
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Therapeutics Assessment 27
Assessment by Mechanism of Action 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Companies Involved in Therapeutics Development 32
4SC AG 32
Celgene Corp 32
Chipscreen Biosciences Ltd 33
Curis Inc 34
HitGen LTD 35
IRBM Science Park SpA 35
Italfarmaco SpA 36
Medivir AB 36
MEI Pharma Inc 37
Merck & Co Inc 37
Mirati Therapeutics Inc 38
Sigma-Tau SpA 39
Syndax Pharmaceuticals Inc 39
Zhejiang Hisun Pharmaceutical Co Ltd 40
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Drug Profiles 41
4SC-202 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
ACY-1035 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ACY-1071 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
ACY-738 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
ACY-957 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
crocetin - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
CS-3158 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
CUDC-907 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
entinostat - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
givinostat - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
HG-3001 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
largazole - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
mocetinostat - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
pracinostat - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
RCY-1305 - Drug Profile 83
Product Description 83
Mechanism Of Action 83
R&D Progress 83
RCY-1497 - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
RCY-1992 - Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
remetinostat - Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
resminostat - Drug Profile 89
Product Description 89
Mechanism Of Action 89
R&D Progress 89
Small Molecule to Inhibit HDAC1, HDAC3 and HDAC6 for Lung Adenocarcinoma - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Small Molecule to Inhibit Histone Deacetylase 1 for Beta Thalassemia - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
Small Molecules to Inhibit HDAC1, HDAC2 and HDAC3 for Oncology - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
ST-3595 - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Synthetic Peptide to Inhibit HDAC for Prostate Cancer - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
tucidinostat - Drug Profile 105
Product Description 105
Mechanism Of Action 105
R&D Progress 105
vorinostat - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Dormant Products 114
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Discontinued Products 117
Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Product Development Milestones 118
Featured News & Press Releases 118
Aug 02, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 118
Jul 19, 2017: Regenacy Pharmaceuticals Presents Data Demonstrating that HDAC1,2 Inhibition Improved Cognitive Function in Mouse Models of Alzheimer's Disease at the Alzheimer's Association International Conference 119
Jul 11, 2017: Preclinical Results Support Entinostat's Role in Targeting the Tumor Microenvironment to Enhance Immune Checkpoint Therapy 119
Jun 14, 2017: Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome 120
Jun 05, 2017: Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 121
May 25, 2017: Curis Announces Presentation Related to CUDC-907 at 2017 ASCO Annual Meeting 122
May 18, 2017: Helsinn Group and MEI Pharma Announce Upcoming Presentations of Gene Mutation and Clinical Response Data from Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia 122
May 17, 2017: Syndax Announces Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) for the Treatment of Advanced Melanoma 123
May 16, 2017: Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies 124
Apr 20, 2017: Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting 125
Apr 19, 2017: GNTbm to begin Phase III clinical trial in Taiwan of epigenetic regulator Chidamide for late-stage breast cancer 125
Apr 11, 2017: New mechanistic insights into 4SC-202’s epigenetic mode of action 126
Apr 07, 2017: Medivir announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma 127
Jan 24, 2017: Overall survival benefit for resminostat in first-line liver cancer study subgroup 128
Jan 11, 2017: Regenacy Pharma's HDAC1 Inhibitor ACY-957 Demonstrates Potent Anti-Leukemic Activities 128
Appendix 130
Methodology 130
Coverage 130
Secondary Research 130
Primary Research 130
Expert Panel Validation 130
Contact Us 130
Disclaimer 131
List of Tables
Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Indications, H2 2017 11
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 14
Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 15
Number of Products under Development by Indications, H2 2017 (Contd..4), H2 2017 16
Number of Products under Development by Companies, H2 2017 17
Products under Development by Companies, H2 2017 18
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 19
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 20
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 21
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 22
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 23
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 24
Number of Products under Investigation by Universities/Institutes, H2 2017 25
Products under Investigation by Universities/Institutes, H2 2017 26
Number of Products by Stage and Mechanism of Actions, H2 2017 27
Number of Products by Stage and Route of Administration, H2 2017 29
Number of Products by Stage and Molecule Type, H2 2017 31
Pipeline by 4SC AG, H2 2017 32
Pipeline by Celgene Corp, H2 2017 33
Pipeline by Chipscreen Biosciences Ltd, H2 2017 34
Pipeline by Curis Inc, H2 2017 35
Pipeline by HitGen LTD, H2 2017 35
Pipeline by IRBM Science Park SpA, H2 2017 36
Pipeline by Italfarmaco SpA, H2 2017 36
Pipeline by Medivir AB, H2 2017 37
Pipeline by MEI Pharma Inc, H2 2017 37
Pipeline by Merck & Co Inc, H2 2017 38
Pipeline by Mirati Therapeutics Inc, H2 2017 39
Pipeline by Sigma-Tau SpA, H2 2017 39
Pipeline by Syndax Pharmaceuticals Inc, H2 2017 40
Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H2 2017 40
Dormant Products, H2 2017 114
Dormant Products, H2 2017 (Contd..1), H2 2017 115
Dormant Products, H2 2017 (Contd..2), H2 2017 116
Discontinued Products, H2 2017 117
List of Figures
Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Top 10 Indications, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 27
Number of Products by Routes of Administration, H2 2017 28
Number of Products by Stage and Routes of Administration, H2 2017 28
Number of Products by Molecule Types, H2 2017 30
Number of Products by Stage and Molecule Types, H2 2017 30
